Paradigm Therapeutics, Inc.
PrivateLast Round
Series B
Extension
Jun 18, 2025
Total Funding Raised
$25.1M
Company Overview
Paradigm Therapeutics, Inc. is a biopharmaceutical company that develops innovative therapies for the treatment of rare diseases, including its lead therapy Zorblisa™ for Epidermolysis Bullosa (EB).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Paradigm Therapeutics, Inc. Comps
Public and private peers based on sector, stage, and business model.
Paradigm Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 18, 2025 | ||||
| Series B | May 6, 2025 |
Key People
Founding team and executive leadership
Paradigm Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Eshelman Ventures | Series B Extension, Series B |
Paradigm Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Paradigm Therapeutics, Inc.'s valuation, stock price, and market status.
